Navigation Links
Oncothyreon announces issuance of patent for PX-867
Date:3/20/2008

have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to filing an IND for PX-866, future clinical development plans for PX-866, and plans to seek a collaboration partner for PX-867. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of PX-866 and PX-867, and the likelihood of achieving a collaboration agreement for PX-867. There can be no guarantee that the results of preclinical studies will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncothyreon to present at upcoming investment conferences
2. Oncothyreon reports full year and fourth quarter 2007 financial results
3. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
4. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
5. Oncothyreon launches new corporate website
6. Oncothyreon to present at BIO CEO & Investor Conference
7. Oncothyreon highlights corporate and clinical objectives for 2008
8. Biomira announces plan to change name to Oncothyreon
9. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
10. Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up
11. BioMS Medical Announces 2007 Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 Tabletop SEMs are ... SEMs but have limited performance and capability such as ... size SEMs would normally provide better imaging performance and ... operate and have a higher cost of maintenance. ... gap between these two types of SEM product, offering ...
(Date:6/18/2013)... June 17, 2013) A million electric cars could be ... decade with the help of research by the United States ... of Waterloo. , Professor Zhongwei Chen is part of a ... develop non-precious materials to replace the expensive platinum catalysts in ... adoption of fuel cells in vehicles is the cost of ...
(Date:6/18/2013)... China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell ... preliminary unaudited financial results for the fourth quarter and ... 2013. Fourth Quarter of Fiscal 2013 ... fiscal 2013 increased by 33.3% to RMB133.0 million ($21.4 ...
(Date:6/18/2013)... New York, NY (PRWEB) June 18, 2013 ... technological innovation and sustainability, the Consulate General of Switzerland ... largest solar boat, Switzerland’s MS Tûranor PlanetSolar , ... as part of its DeepWater Expedition 2013 tour with ... catamaran, led by Capitain Gérard d’Aboville, runs exclusively on ...
Breaking Biology Technology:Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3US and Canadian researchers drive towards cheaper fuel cells for electric cars 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4
... CellCyte Genetics,Corporation (CellCyte) (OTC Bulletin Board: CCYG) ... investment and financial advice and,services. CellCyte seeks to ... technologies and will work with InCap to initiate ... of,CellCyte,s cell expander and stem cell delivery technologies., ...
... China, July 9 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), ... development outsourcing company with operations in China and ... D. Bryans, Vice President,and General Manager of WuXi ... of WuXi PharmaTech (Cayman) Inc., has been invited,to ...
... organic light-emitting diodes, require a transparent conductive layer with ... electron holes into an organic layer to produce more ... the International Conference on Science and Technology of Synthetic ... the injection efficiency. A balanced injection of positive and ...
Cached Biology Technology:CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 4WuXi AppTec VP and GM Invited to Join the AAMI Standards Board 2WuXi AppTec VP and GM Invited to Join the AAMI Standards Board 3Research helps understand factors that influence efficiency of organic-based devices 2Research helps understand factors that influence efficiency of organic-based devices 3
(Date:6/18/2013)... 2013  Paris Air Show – Marvin ... , a leading provider of innovative test solutions ... its solutions this week at the Paris ... challenges including increasingly complex armament systems with longer ... aerospace test solutions that address legacy system obsolescence. ...
(Date:6/18/2013)... of Medicine have discovered a mechanism that is used ... component of blood typically associated with clotting, were discovered ... seal it off from the rest of the body. ... this week, provide the science community with a ... known that platelets do participate in immunity, but now ...
(Date:6/18/2013)... Energy Department,s National Renewable Energy Laboratory (NREL), and ... paper describing a novel cellulose-degrading enzyme from a ... known as the gribble. , Gribbles are ... ability to produce their own enzymes instead of ... they eat. New biomass-degrading enzymes from novel sources ...
Breaking Biology News(10 mins):Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Immunity mechanism discovered 2Novel enzyme from tiny gribble could prove a boon for biofuels research 2
... 2011-- The Donald Danforth Plant Science Center announced today ... for the Virus Resistant Cassava for Africa (VIRCA) project ... wellbeing of farmers, their families, and other consumers of ... will be used to support Phase II of the ...
... A U.S. Department of Agriculture (USDA) aerial photography ... is believed to be the first evidence that the ... mountain big sagebrush. Terry Booth, a rangeland specialist ... Unit in Cheyenne, Wyo., designed the survey using a ...
... Australia, September 6, 2011 Eight IOF Young Investigator ... to young researchers from Australia, China, India and Japan, ... at 1,000 USD each, were awarded to the highest ... The presentations were made on September ...
Cached Biology News:Danforth Center Collaborative Research Program receives funding to improve crop yield in Africa 2Danforth Center Collaborative Research Program receives funding to improve crop yield in Africa 3Digital cameras open new view of America's West 2
... Pro-mix l-[35S]in vitro cell ... mCi. *Aqueous solution stabilized ... 15 mM pyridine 3,4-dicarboxylic acid. ... vitro protein labeling containing l-[35S]Methionine ...
... Assay, 96 wells. ELISA.Specific for total ... MMP-3. No cross-reactivity with MMP-1, -2, -9. ... use with cell culture supernatant, serum, plasma ... to -30 C. Category: Drug Screening ...
... Designed for serial preparation ... fractions including cytosol/particulate/cytoskeleton/nuclear fractions ... these fractions can directly ... assays such as 2-D ...
Self Closing Forceps...
Biology Products: